NCT00365378View on ClinicalTrials.gov

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

PHASE2CompletedINTERVENTIONAL

Enrollment

2,409

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

March 31, 2004

Study Completion Date

July 31, 2009

Conditions

HPV 16 Infection

Interventions

BIOLOGICAL

Comparator: HPV 16 L1 Vaccine

A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6

BIOLOGICAL

Comparator: Placebo

A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00365378 - Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) | Biotech Hunter | Biotech Hunter